



Vivimed

Date:13/02/2015

To

BSE Limited
Listing Department
P.J.Towers,Dalal Street,
Mumbai – 400001

BSE - Scripe Code : 532660

National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E),Mumbai – 400051

NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg

The Board of Directors of the Company at its meeting held on 13TH February, 2015, inter alia, have approved/resolved/taken note of the following:

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchanges, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter ended 31ST December,2014 attached herewith;

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com

You are requested to take note of the above.

Yours faithfully

For **VIVIMED LABS LTD**



SANTOSH VARALWAR
MANAGING DIRECTOR & CEO

Vivimed Labs Ltd (Head Office)

CIN : L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, T.S. 500 007, India

T+91 (0) 40-2717 6005/6 F+91 (0) 40-2715 0599

info@vivimedlabs.com www.vivimedlabs.com

VIVIMED LABS LIMITED
CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS ENDED DEC '31' ST 2014

₹ In Lacs

Sl. No.	Particulars	Quarter Ended				9 Months Ended		Previous Year ended 31.03.2014 FY 14
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013		
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	34,370.99	31,363.86	33,526.56	102,388.40	98,265.98	135,083.30	
	(b) Other Operating Income	98.62	315.71	50.77	724.11	431.09	821.51	
	Total Income From Operations (Net)	34,469.61	31,679.58	33,577.33	103,112.50	98,697.07	135,904.81	
	a. Cost of Raw Materials Consumed	17,292.61	16,718.48	17,476.65	52,772.58	47,127.55	66,370.82	
	b. Purchase of Stock in Trade							
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(1,516.56)	(1,917.53)	(1,489.44)	(4,883.41)	2,456.53	(738.38)	
	d. Employee Benefit Expenses	4,780.18	4,225.10	4,494.47	13,721.67	11,845.89	17,206.48	
	e. Depreciation and Amortisation Expenses	1,843.10	1,653.82	1,693.98	5,147.06	4,896.66	6,611.62	
	f. Other Expenditure	7,886.57	7,474.68	7,735.54	24,301.97	21,784.70	31,739.01	
2	Total Expenses	30,285.90	28,154.54	29,911.20	91,059.87	88,111.33	121,189.55	
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional Items (1 - 2)	4,183.61	3,525.04	3,666.13	12,052.63	10,585.74	14,715.26	
4	Other Income							
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional Items (3 - 4)	4,183.61	3,525.04	3,666.13	12,052.63	10,585.74	14,715.26	
6	Finance Costs	1,937.23	1,968.75	1,564.84	5,933.68	4,265.60	6,029.10	
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional Items (5 - 6)	2,246.38	1,556.29	2,101.29	6,118.95	6,320.14	8,686.16	
8	Exceptional Items							
9	Profit / Loss from ordinary activities before Tax (7 - 8)	2,246.38	1,556.29	2,101.29	6,118.95	6,320.14	8,686.16	
10	Tax Expenses	190.28	(84.79)	202.48	708.73	784.91	2,046.76	
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	2,056.09	1,641.07	1,898.81	5,410.21	5,535.23	6,639.41	
12	Extraordinary Items (net of tax expenses Re.....Lacs)							
13	Net Profit / Loss for period (11 - 12)	2,056.09	1,641.07	1,898.81	5,410.21	5,535.23	6,639.41	
14	Share of Profit / (Loss) of associates							
15	Minority Interest							
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	2,056.09	1,641.07	1,898.81	5,410.21	5,535.23	6,639.41	
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year							
19	Earnings per Share (before Extraordinary Items) (of Rs.10/- each) (not annualised)							
	(a) Basic	12.69	10.13	11.72	33.39	34.16	40.97	
	(b) Diluted	12.69	10.13	11.72	33.39	34.16	40.97	

1. The above Consolidated Unaudited Financial Results for the quarter ended & 9 Months ended December 31st 2014 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 13th February 2015

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Kar Schen Private Limited, (iv) Octant's Nobel Labs Private Limited, (v) Vivimed Labs (Alathur) Pvt Limited (vi) Finsso Pharma Pvt Limited (vii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (viii) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico Farmaceutica S.A.U., Spain, (iv) Holiday International Limited UK & (v) Uquifa Mexico S.A. de C.V.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

6. This quarter is the balancing figure of the YTD and the reported for last quarters.

7. Depreciation has been calculated basing on the provisions of the companies Act 2013

For VIVIMED LABS LIMITED



(SANTOSH JAGALWAR)
 MANAGING DIRECTOR & CEO

Place : Hyderabad

Date : 13.02.2015

